Association of CSF α-synuclein seed amplification assay positivity with disease progression and cognitive decline: A longitudinal Alzheimer's Disease Neuroimaging Initiative study.
Alzheimer's disease
Lewy body
cognitive decline
co‐pathology
seed amplification assay
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
20 Oct 2024
20 Oct 2024
Historique:
revised:
28
08
2024
received:
17
06
2024
accepted:
30
08
2024
medline:
21
10
2024
pubmed:
21
10
2024
entrez:
21
10
2024
Statut:
aheadofprint
Résumé
Cerebrospinal fluid (CSF) α-synuclein (α-syn) seed amplification assay (SAA) is a sensitive and specific tool for detecting Lewy body co-pathology in Alzheimer's disease. A total of 1637 cross-sectional and 407 longitudinal CSF samples from the Alzheimer's Disease Neuroimaging Initiative (ADNI) were tested with SAA. We examined longitudinal dynamics of amyloid beta (Aβ), α-syn seeds, and phosphorylated tau181 (p-tau181), along with global and domain-specific cognition in stable SAA+, stable SAA-, and those who converted to SAA+ from SAA-. SAA+ individuals had faster cognitive decline than SAA-, notably in mild cognitive impairment, and presented with earlier symptom onset. SAA+ conversion was associated with CSF Aβ42 positivity but did not impact the progression of either CSF Aβ42 or CSF p-tau181 status. CSF Aβ42, p-tau181, and α-syn SAA were all strong predictors of clinical progression, particularly CSF Aβ42. In vitro, CSF α-syn SAA kinetic parameters were associated with participant demographics, clinical profiles, and cognitive decline. These results highlight the interplay between amyloid and α-syn and their association with disease progression. Seed amplification assay (SAA) positivity was associated with greater cognitive decline and earlier symptom onset. Thirty-four Alzheimer's Disease Neuroimaging Initiative (ADNI) individuals progressed from SAA- to SAA+, that is, ≈ 5% conversion. SAA conversion was associated with amyloid beta (Aβ) pathology and greater cognitive decline. SAA status did not impact the progression of either CSF Aβ42 or phosphorylated tau181 biomarkers. Change in clinical diagnosis was associated with both Alzheimer's disease biomarkers and SAA. SAA kinetic parameters were associated with clinical features and progression.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Genentech, Inc
Organisme : NIH/NIA
ID : U19AG024904
Informations de copyright
© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha‐synuclein immunohistochemistry. Brain Pathol. 2000;10:378‐384.
Mikolaenko I, Pletnikova O, Kawas CH, et al. Alpha‐synuclein lesions in normal aging, Parkinson's disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol. 2005;64:156‐162.
Kovacs GG, Milenkovic I, Wöhrer A, et al. Non‐Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community‐based autopsy series. Acta Neuropathol. 2013;126:365‐384..
Spina S, La Joie R, Petersen C, et al. Comorbid neuropathological diagnoses in early versus late‐onset Alzheimer's disease. Brain. 2021;144:2186‐2198.
Lippa CF, Fujiwara H, Mann DM, et al. Lewy bodies contain altered alpha‐synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol. 1998;153:1365‐1370.
Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ. Antibodies to alpha‐synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann Neurol. 1999;45:353‐357.
Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology. 1990;40:1‐8.
Braak H, Braak E. Neuropathological stageing of Alzheimer‐related changes. Acta Neuropathol. 1991;82:239‐259.
Thal DR, Rüb U, Orantes M, Braak H. Phases of A beta‐deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791‐1800.
Mandal PK, Pettegrew JW, Masliah E, Hamilton RL, Mandal R. Interaction between abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochem Res. 2006;31:1153‐1162.
Tsigelny IF, Crews L, Desplats P, et al. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS One. 2008;3:e3135.
Ono K, Takahashi R, Ikeda T, Yamada M. Cross‐seeding effects of amyloid β‐protein and α‐synuclein. J Neurochem. 2012;122:883‐890.
Bassil F, Brown HJ, Pattabhiraman S, et al. Amyloid‐beta (Aβ) plaques promote seeding and spreading of alpha‐synuclein and tau in a mouse model of Lewy body disorders with Aβ pathology. Neuron. 2020;105:260‐275.e6.
Goedert M, Spillantini MG. A century of Alzheimer's disease. Science. 2006;314:777‐781.
Ngolab J, Trinh I, Rockenstein E, et al. Brain‐derived exosomes from dementia with Lewy bodies propagate α‐synuclein pathology. Acta Neuropathol Commun. 2017;5:46.
Palmqvist S, Rossi M, Hall S, et al. Cognitive effects of Lewy body pathology in clinically unimpaired individuals. Nat Med. 2023;29:1971‐1978.
Quadalti C, Palmqvist S, Hall S, et al. Clinical effects of Lewy body pathology in cognitively impaired individuals. Nat Med. 2023;29:1964‐1970.
Bellomo G, Paciotti S, Concha‐Marambio L, et al. Cerebrospinal fluid lipoproteins inhibit α‐synuclein aggregation by interacting with oligomeric species in seed amplification assays. Mol Neurodegener. 2023;18:20.
Tosun D, Hausle Z, Iwaki H, et al. A cross‐sectional study of α‐synuclein seed amplification assay in Alzheimer's Disease Neuroimaging Initiative: prevalence and associations with Alzheimer's disease biomarkers and cognitive function. Alzheimers Dement. 2024;20:5114‐5131.
Boyle PA, Wang T, Yu L, et al. To what degree is late life cognitive decline driven by age‐related neuropathologies? Brain. 2021;144:2166‐2175.
Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 2017;134:171‐186.
Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer's disease. N Engl J Med. 2021;384:1691‐1704.
Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. J Prev Alzheimers Dis. 2022;9:197‐210.
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2022;388:9‐21.
Robinson JL, Lee EB, Xie SX, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age‐related and APOE4‐associated. Brain. 2018;141:2181‐2193.
Tsuang D, Leverenz JB, Lopez OL, et al. APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol. 2013;70:223‐228.
Tsuang DW, Wilson RK, Lopez OL, et al. Genetic association between the APOE*4 allele and Lewy bodies in Alzheimer disease. Neurology. 2005;64:509‐513.
Dickson DW, Heckman MG, Murray ME, et al. APOE ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology. 2018;91:e1182‐e1195.
Gharbi A, Nasri A, Sghaier I, et al. Subtypes of dementia with Lewy bodies: clinical features, survival, and apolipoprotein E effect. J Alzheimers Dis Rep. 2023;7:1277‐1288.
Real R, Martinez‐Carrasco A, Reynolds RH, et al. Association between the LRP1B and APOE loci and the development of Parkinson's disease dementia. Brain. 2023;146:1873‐1887.
Jin Y, Li F, Sonoustoun B, et al. APOE4 exacerbates α‐synuclein seeding activity and contributes to neurotoxicity in Alzheimer's disease with Lewy body pathology. Acta Neuropathol. 2022;143:641‐662.
Betthauser TJ, Bilgel M, Koscik RL, et al. Multi‐method investigation of factors influencing amyloid onset and impairment in three cohorts. Brain. 2022;145:4065‐4079.
Crane PK, Choi S‐E, Gibbons LE, et al. Cognitive assessments in ADNI: lessons learned from the ADNI psychometrics project. Alzheimers Dement. 2021;17:e056474.
Diamond A, Sekhon JS. Genetic matching for estimating causal effects: a general multivariate matching method for achieving balance in observational studies. Rev Econ Stat. 2013;95:932‐945.
Sekhon JS. Multivariate and propensity score matching software with automated balance optimization: the matching package for R. J Stat Softw. 2011;42:1‐52.
Selya AS, Rose JS, Dierker LC, Hedeker D, Mermelstein RJ. A practical guide to calculating Cohen's f(2), a measure of local effect size, from PROC MIXED. Front Psychol. 2012;3:111.
Malek‐Ahmadi M, Beach TG, Zamrini E, et al. Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease. PLoS One. 2019;14:e0217566.
Twohig D, Nielsen HM. α‐Synuclein in the pathophysiology of Alzheimer's disease. Mol Neurodegener. 2019;14:23.
Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66:200‐208.
van der Gaag BL, Deshayes NAC, Breve JJP, Bol J, Jonker AJ, Hoozemans JJM, et al. Distinct tau and alpha‐synuclein molecular signatures in Alzheimer's disease with and without Lewy bodies and Parkinson's disease with dementia. Acta Neuropathol. 2024;147:14.
Marsh SE, Blurton‐Jones M. Examining the mechanisms that link β‐amyloid and α‐synuclein pathologies. Alzheimers Res Ther. 2012;4:11.
Bräuer S, Rossi M, Sajapin J, et al. Kinetic parameters of alpha‐synuclein seed amplification assay correlate with cognitive impairment in patients with Lewy body disorders. Acta Neuropathol Commun. 2023;11:162.
Brockmann K, Lerche S, Baiardi S, et al. CSF α‐synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson's disease. NPJ Parkinson's Disease. 2024;10:24.